Peer-Reviewed Data Reinforces GeoVax's Multi-Antigen Strategy With GEO-CM02 and Supports Advancement of GEO-CM04S1 Clinical ...

Oncology, and Biosecurity Amid Strategic Program Developments ATLANTA, GA - April 16, 2025 (NEWMEDIAWIRE) - GeoVax Labs, Inc.

GeoVax was using its HHS contract to develop its next-generation multi-antigen COVID-19 vaccine, which is in Phase IIb ...

Despite the PNG award termination, GeoVax anticipates a milestone-rich 2025 across its portfolio. The Company will continue to engage with government and industry partners, pursue clinical trial ...

The U.S. government continues to end contracts related to the $5 billion Project NextGen initiative, this time terminating ...

On April 11, 2025, GeoVax Labs, Inc. (NASDAQ:GOVX), a biotechnology company specializing in developing human vaccines with a market capitalization of $14.39 million, was instructed to halt all ...

According to TipRanks.com, LeBoyer is ranked 0 out of 5 stars with an average return of -12.8% and a 26.3% success rate. LeBoyer covers the Healthcare sector, focusing on stocks such as Cadrenal ...

On April 11, 2025, GeoVax Labs, Inc. (NASDAQ:GOVX), a biotechnology company specializing in developing human vaccines with a market capitalization of $14.39 million, was instructed to halt all ...

GeoVax Labs, Inc. (NASDAQ:GOVX) Q4 2024 Earnings Call Transcript March 27, 2025 GeoVax Labs, Inc. beats earnings expectations. Reported EPS is $-0.3, expectations were $-0.79. Operator ...

Good afternoon. And welcome everyone to the GeoVax Fourth Quarter Full Year 2024 Corporate Update Call. My name is Michelle and I will facilitate today’s call. With me are David Dodd ...